Phase 1 vs Phase 2 — Rare Disease Deal Valuation Comparison

Phase 1 Median Upfront

$91M

Total: $846M

Phase 2 Median Upfront

$285M

Total: $1.6B

Stage Premium

86%

Phase 2 premium over Phase 1

Phase 1 Royalties

5.6%-11.2%

vs Phase 2: 7.8%-15.6%

Model Your Deal

Market Analysis

The Phase 1 to Phase 2 transition in rare disease represents a significant value inflection point. Phase 2 deals carry a median total deal value of $1.6B compared to $846M at Phase 1, a 86% premium reflecting clinical de-risking. Upfront payments increase from $91M to $285M.

Deal structures shift as assets advance. Phase 1 deals allocate 11% to upfront and 89% to milestones, while Phase 2 deals shift to 18%/82%. Development milestones move from $264M to $283M, and royalty rates evolve from 5.6%-11.2% to 7.8%-15.6%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 1 to Phase 2 in rare disease?

Phase 2 rare disease deals command a 86% premium over Phase 1 in total deal value ($1.6B vs $846M). Upfronts increase from $91M to $285M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 1 and Phase 2 in rare disease?

Phase 1 deals are more milestone-weighted (89% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (18% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a rare disease asset?

The optimal licensing window depends on strategic priorities. Phase 1 assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 86% premium from Phase 1 to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included